Asia Pacific Cancer Immunotherapy Market Size & Outlook
Asia Pacific cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Asia Pacific cancer immunotherapy market highlights
- The Asia Pacific cancer immunotherapy market generated a revenue of USD 26,882.4 million in 2023.
- The market is expected to grow at a CAGR of 11.9% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 26,882.4 million |
| Market revenue in 2030 | USD 59,131.5 million |
| Growth rate | 11.9% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 21.4% of the global cancer immunotherapy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 59,131.5 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 68.16% in 2023. Horizon Databook has segmented the Asia Pacific cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The cancer immunotherapy market in Asia Pacific is expected to grow at a significant rate during the forecast period due to the presence of leading oncology companies and increase in R&D investments in countries such as China and Japan.
This, in turn, has led to an increase in the development of cancer drugs. Moreover, the cost of clinical trials in developing countries is lesser than that in developed countries. In addition, developing countries such as India and China are witnessing an increase in population and disposable income.
High incidence of cancer in this region has resulted in an increase in the demand for improved therapeutics, rise in government funding for cancer & other research, and increase in healthcare expenditure. Thus, these factors are expected to drive market growth in Asia Pacific during the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific cancer immunotherapy market size, by country, 2018-2030 (US$M)
Asia Pacific Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
